Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BASIOTCMKTS:CBWTFNASDAQ:ELOXNASDAQ:LUNANASDAQ:PIRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBASIBioanalytical Systems$1.82+7.1%$18.71$3.05▼$21.08$20.26M1.92122,925 shs371,528 shsCBWTFCannabis Wheaton Income$0.08+0.9%$0.06$0.02▼$0.08$99.26M1.04813,992 shs768,278 shsELOXEloxx Pharmaceuticals$0.11$0.00▼$0.84N/A-1536.271,618 shs6 shsLUNALuna Innovations$0.90+1.7%$0.56$0.22▼$3.39$30.56M1.88196,092 shs8,130 shsPIRSPieris Pharmaceuticals$13.60$15.17$6.20▼$18.68$17.95M0.6184,553 shs51,728 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBASIBioanalytical Systems0.00%-17.07%-34.62%-23.08%+2.41%CBWTFCannabis Wheaton Income+9.13%+25.50%+23.04%+26.55%+258.57%ELOXEloxx Pharmaceuticals0.00%0.00%0.00%0.00%-99.99%LUNALuna Innovations-1.67%+18.00%+77.00%+58.04%-72.34%PIRSPieris Pharmaceuticals0.00%0.00%0.00%0.00%+38.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBASIBioanalytical SystemsN/AN/AN/AN/AN/AN/AN/AN/ACBWTFCannabis Wheaton IncomeN/AN/AN/AN/AN/AN/AN/AN/AELOXEloxx PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ALUNALuna Innovations0.2592 of 5 stars0.01.00.00.02.51.70.0PIRSPieris PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBASIBioanalytical Systems 0.00N/AN/AN/ACBWTFCannabis Wheaton Income 0.00N/AN/AN/AELOXEloxx Pharmaceuticals 0.00N/AN/AN/ALUNALuna Innovations 0.00N/AN/AN/APIRSPieris Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBASIBioanalytical Systems$60.47M0.34$0.00 per share558.40$0.69 per share2.64CBWTFCannabis Wheaton Income$89.29M1.12N/AN/A$0.06 per share1.27ELOXEloxx PharmaceuticalsN/AN/AN/AN/AN/AN/ALUNALuna Innovations$116.61M0.26$0.30 per share3.03N/A∞PIRSPieris Pharmaceuticals$42.81M0.42N/AN/A$21.66 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBASIBioanalytical Systems-$4.68M-$0.35N/A45.50N/A-7.75%-42.74%-6.38%N/ACBWTFCannabis Wheaton Income-$11.93M$0.017.61∞N/A16.56%18.53%8.13%N/AELOXEloxx Pharmaceuticals-$36.06MN/A0.00N/AN/AN/AN/AN/AN/ALUNALuna Innovations$9.28MN/A0.00∞N/AN/AN/AN/AN/APIRSPieris Pharmaceuticals-$24.54M-$12.10N/A∞N/A-39.71%-80.93%-59.55%N/ALatest BASI, CBWTF, PIRS, LUNA, and ELOX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CBWTFCannabis Wheaton IncomeN/A$0.01N/A$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBASIBioanalytical SystemsN/AN/AN/AN/AN/ACBWTFCannabis Wheaton IncomeN/AN/AN/AN/AN/AELOXEloxx PharmaceuticalsN/AN/AN/AN/AN/ALUNALuna InnovationsN/AN/AN/AN/AN/APIRSPieris PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBASIBioanalytical Systems2.490.480.46CBWTFCannabis Wheaton Income0.020.680.34ELOXEloxx PharmaceuticalsN/AN/AN/ALUNALuna InnovationsN/AN/AN/APIRSPieris PharmaceuticalsN/A4.824.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBASIBioanalytical Systems10.62%CBWTFCannabis Wheaton IncomeN/AELOXEloxx Pharmaceuticals2.90%LUNALuna Innovations87.46%PIRSPieris Pharmaceuticals40.11%Insider OwnershipCompanyInsider OwnershipBASIBioanalytical Systems11.46%CBWTFCannabis Wheaton Income4.60%ELOXEloxx Pharmaceuticals20.20%LUNALuna Innovations7.60%PIRSPieris Pharmaceuticals6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBASIBioanalytical Systems39711.13 millionN/ANot OptionableCBWTFCannabis Wheaton Income3691.32 billion1.26 billionNot OptionableELOXEloxx Pharmaceuticals303.14 million2.51 millionNot OptionableLUNALuna Innovations39033.96 million31.38 millionOptionablePIRSPieris Pharmaceuticals1401.32 million1.24 millionOptionableBASI, CBWTF, PIRS, LUNA, and ELOX HeadlinesRecent News About These CompaniesPieris Pharmaceuticals IncApril 18, 2025 | money.usnews.comPalvella Therapeutics Inc (PVLA)December 27, 2024 | investing.comMain Line biotech firm completes reverse merger, raises $78.9 millionDecember 17, 2024 | bizjournals.comOne new option listing and one option delisting on December 16thDecember 17, 2024 | markets.businessinsider.comPalvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease TreatmentsDecember 14, 2024 | msn.comPalvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 MillionDecember 14, 2024 | markets.businessinsider.com(PIRS) Trading ReportNovember 27, 2024 | news.stocktradersdaily.comNPIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRSNovember 20, 2024 | businesswire.comHow To Trade (PIRS)November 17, 2024 | news.stocktradersdaily.comNPieris Pharmaceuticals announces first patient dosed in SELVA Phase 3 trialNovember 7, 2024 | markets.businessinsider.com(PIRS) Investment Analysis and AdviceNovember 6, 2024 | news.stocktradersdaily.comNPieris loses Servier as partner for cancer immunotherapiesOctober 29, 2024 | pharmaphorum.comP(PIRS) Technical DataOctober 26, 2024 | news.stocktradersdaily.comNAridis Pharmaceuticals (OTC:ARDS) Stock Quotes, Forecast and News SummaryOctober 19, 2024 | benzinga.comLearn to Evaluate (PIRS) using the ChartsOctober 16, 2024 | news.stocktradersdaily.comNPalvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual ConferenceOctober 15, 2024 | globenewswire.com(PIRS) Trading SignalsOctober 7, 2024 | news.stocktradersdaily.comNPalvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic MalformationsOctober 3, 2024 | globenewswire.comKubota Pharmaceutical Holdings Co., Ltd. (4596.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comPieris Pharmaceuticals Inc.September 24, 2024 | barrons.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryBASI, CBWTF, PIRS, LUNA, and ELOX Company DescriptionsBioanalytical Systems NASDAQ:BASIBioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. BioVaxys has an agreement with Inotiv to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.Cannabis Wheaton Income OTCMKTS:CBWTF$0.08 +0.00 (+0.93%) As of 03:54 PM EasternAuxly Cannabis Group Inc. operates as a consumer packaged goods company in the cannabis products market in Canada. It focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. The company offers cannabis products under various forms, including vape catridges, infused pre-rolls, pre-rolled, vape pens, milled and dried flower, concentrates, chocolates, soft chews, oil drops, capsules, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names. It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. The company was incorporated in 1987 and is headquartered in Toronto, Canada.Eloxx Pharmaceuticals NASDAQ:ELOXEloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.Luna Innovations NASDAQ:LUNA$0.90 +0.02 (+1.69%) As of 03:30 PM EasternLuna Innovations Incorporated provides fiber optic test, measurement, and control products worldwide. The company offers test and measurement equipment for fiber optic components and sub-assemblies; polarization control products, including components, modules, and instruments to measure, manage, and control polarization and group delay in fiber optic networks; tunable lasers; and single frequency lasers. It also provides ODiSI sensing solution, which provides distributed strain and temperature measurements; distributed temperature sensing system; hyperion sensing products; Terahertz Sensing Systems that provide precise single and multi-layer thickness, density, basis weight, and caliper thickness measurements; and distributed acoustic sensing products. The company primarily markets its fiber optic test, measurement, and control products to telecommunications companies, defense agencies, government system integrators, researchers, original equipment manufacturers, distributors, testing labs, and strategic partners directly, as well as through manufacturer representative organizations, partner and distribution channels, technical sales engineers, value added resellers, and independent sales representatives. Luna Innovations Incorporated was incorporated in 1990 and is headquartered in Roanoke, Virginia.Pieris Pharmaceuticals NASDAQ:PIRSPieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
